NCT05751044 2025-09-16
HEM-iSMART B
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
Clinical Trials
11 trialsNCT03560908 2025-05-01
Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Withdrawn
NCT05432518 2025-04-25
Pilot Trial for Treatment of Recurrent Glioblastoma
AHS Cancer Control Alberta
Phase EARLY_PHASE1 Recruiting
NCT02081378 2024-03-18
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
Novartis
Phase 1 Completed
NCT04603872 2020-10-28
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT00036738 2020-01-29
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00949988 2019-08-14
BMS-CA180105
University of California, San Diego
Phase 1/2 Terminated
NCT01488318 2018-01-05
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
University of Pittsburgh
Phase 2 Terminated
NCT01173679 2017-04-14
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL
Massachusetts General Hospital
Phase 2 Terminated
NCT01116128 2011-06-14
D-MP
Fondazione EMN Italy Onlus
Phase 2 Terminated
NCT00371345 2011-04-26
Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer
Bristol-Myers Squibb
Phase 2 Completed